[EN] COMPOUNDS AND COMPOSITIONS THAT CAUSE MYCN AND/OR CMYC DEGRADATION AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS ET COMPOSITIONS QUI PROVOQUENT LA DÉGRADATION DE MYCN ET/OU DE CMYC ET LEURS PROCÉDÉS D'UTILISATION
申请人:UNIV COLUMBIA
公开号:WO2020123699A1
公开(公告)日:2020-06-18
The present disclosure provides, inter alia, scaffolds and compounds having the structure (I). Also provided are compositions containing a pharmaceutically acceptable carrier and one or more compounds according to the present disclosure. Further provided are methods for treating or ameliorating the effects of a cancer in a subject, methods for selectively killing a cancer cell, methods of modulating mTORC1/2 signaling activity in a cell, methods of modulating the activity of a Master Regulator for MycN in a subject having MycN-amplified neuroblastoma (MycNAMP NBL), methods of selectively treating or ameliorating effects of a cancer in a subject in need thereof, and platforms and methods for identifying a compound that induces degradation of a cancer-related protein. Also provided are kits comprising a compound or a pharmaceutical composition according to the present disclosure. Methods for treating cancers and methods for modulating MYC Master Regulators using other compounds are also provided.
Osage Orange Pigments. II. Isolation of a New Pigment, Pomiferin
作者:M. L. Wolfrom、F. L. Benton、A. S. Gregory、W. W. Hess、J. E. Mahan、P. W. Morgan
DOI:10.1021/ja01265a079
日期:1939.10.1
BENZOPYRAN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF
申请人:ORLOW Seth J.
公开号:US20120196926A1
公开(公告)日:2012-08-02
Provided are benzopyran compounds of formula I, for example, pomiferin-3′,4′-dimethyl ether, and the use of such compounds and compositions thereof to modulate (e.g., inhibit) melanogenesis and pigmentation.
wherein R
3
, R
4
, R
5
, R
6
, R
7
and R
8
are described herein. Also provided are plant extracts containing a compound of formula I, and the use of such a plant extract to modulate (e.g., inhibit) melanogenesis and pigmentation. The compound or plant extract may be prepared as pharmaceutical and cosmetic compositions, and may be used for the prevention and treatment of conditions that are related to aberrant melanogenesis activity.
COMPOUNDS AND COMPOSITIONS THAT CAUSE MYCN AND/OR CMYC DEGRADATION AND METHODS OF USE THEREOF
申请人:THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
公开号:US20220119399A1
公开(公告)日:2022-04-21
The present disclosure provides, inter alia, scaffolds and compounds having the structure:
Also provided are compositions containing a pharmaceutically acceptable carrier and one or more compounds according to the present disclosure. Further provided are methods for treating or ameliorating the effects of a cancer in a subject, methods for selectively killing a cancer cell, methods of modulating mTORC1/2 signaling activity in a cell, methods of modulating the activity of a Master Regulator for MycN in a subject having MycN-amplified neuroblastoma (MycN
AMP
NBL), methods of selectively treating or ameliorating effects of a cancer in a subject in need thereof, and platforms and methods for identifying a compound that induces degradation of a cancer-related protein. Also provided are kits comprising a compound or a pharmaceutical composition according to the present disclosure. Methods for treating cancers and methods for modulating MYC Master Regulators using other compounds are also provided.